Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation.

Ljungberg C, Bonnesen K, Schmidt M, Vandenbroucke-Grauls C, Dalager-Pedersen M, Sørensen HT, Nørgaard M, Thomsen RW

DOI: 10.1111/dom.70937
Published: 2026 Aug
Container: Diabetes, obesity & metabolism
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/dom.70937,
  title = {Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation.},
  author = {Ljungberg C and Bonnesen K and Schmidt M and Vandenbroucke-Grauls C and Dalager-Pedersen M and Sørensen HT and Nørgaard M and Thomsen RW},
  year = {2026},
  journal = {Diabetes, obesity \& metabolism},
  doi = {10.1111/dom.70937},
  url = {https://doi.org/10.1111/dom.70937}
}

RIS

TY  - JOUR
TI  - Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation.
AU  - Ljungberg C
AU  - Bonnesen K
AU  - Schmidt M
AU  - Vandenbroucke-Grauls C
AU  - Dalager-Pedersen M
AU  - Sørensen HT
AU  - Nørgaard M
AU  - Thomsen RW
PY  - 2026
JO  - Diabetes, obesity & metabolism
DO  - 10.1111/dom.70937
UR  - https://doi.org/10.1111/dom.70937
ER  -

APA

C, L., K, B., M, S., C, V., M, D., HT, S., M, N., & RW, T. (2026). Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70937

Source records

pubmed · retrieved 2026-09-26T11:04:14.604Z